Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit Led by Schall Law Firm

Investors Encouraged to Join REGENXBIO Class Action Against Securities Fraud

In a significant legal development, the Schall Law Firm, a prominent firm specializing in shareholder rights litigation, is calling on investors of REGENXBIO Inc. (NASDAQ: RGNX) to consider participating in a class action lawsuit. This lawsuit is grounded in allegations that the company violated several regulations under the Securities Exchange Act of 1934, particularly focusing on false and misleading statements made to investors.

Understanding the Allegations

The details surrounding these allegations stem from the company's product candidate, RGX-111. Throughout the designated class period—from February 9, 2022, to January 27, 2026—Regenxbio made several positive assertions about the efficacy and safety of RGX-111. However, these claims have come into question following the discovery of negative data that was not disclosed to shareholders. Notably, a serious incident involving an intraventricular CNS tumor was revealed, directly linked to a participant in the RGX-111 study, contradicting the previously optimistic statements by the company’s leadership.

The situation escalated as investors were left in the dark about the actual risks associated with the product, leading to a significant drop in stock value once these truths came to light. This downturn not only resulted in financial losses for many but has also raised questions about the integrity of the company’s communications and its responsibilities to its shareholders.

Invitation to Action

The Schall Law Firm is urging all affected investors who purchased REGENXBIO's securities during the class period to reach out and share their experiences. Specifically, individuals who have incurred losses due to these misleading statements are encouraged to contact the firm before the deadline of April 14, 2026. Involvement in this class action could be a pivotal step in recovering damages incurred due to the alleged securities fraud.

For potential participants, it's worth noting that the class has yet to be certified, meaning that those who do not take action may remain as absent class members without representation.

Free Consultation Available

Investors can seek legal counsel from Brian Schall and his team free of charge, ensuring they understand their rights and the implications of the ongoing lawsuit. The firm can be contacted directly at their offices in Los Angeles or through their website, providing an accessible avenue for investors looking to pursue justice.

The Road Ahead

As this legal case unfolds, it highlights the critical role that transparency and honesty play in corporate communications. Investors are reminded of their rights and that, through collective action, they can hold companies accountable for any alleged wrongdoing. The Schall Law Firm's commitment to representing investors underscores the potential for significant recovery in instances of corporate misconduct.

In conclusion, for those who have stakes in REGENXBIO, now is the time to engage with the ongoing class action lawsuit and explore options for recovery, ensuring that the truth about their investments comes to light and justice can be served.